冠心宁联合单硝酸异山梨酯治疗慢性心力衰竭患者临床疗效及对心功能的影响

目的 观察冠心宁联合单硝酸异山梨酯治疗慢性心力衰竭（CHF）患者临床疗效及对心功能的影响。方法 将2019年1月至2021年12月间安徽省阜阳市肿瘤医院收治的102例CHF患者按随机数字表法分为对照组（单硝酸异山梨酯治疗）和观察组（单硝酸异山梨酯+冠心宁治疗）各51例。比较两组临床疗效、治疗前后超心动图参数左心室收缩末期内径（LVESD）、左室舒张末期内径（LVEDD）、左心室射血分数（LVEF）]、血清心肌酶谱指标乳酸脱氢酶（LDH）、谷草转氨酶（AST）、磷酸肌酸激酶（CK）、磷酸肌酸激酶同工酶（CK-MB）]及血清肌钙蛋白I（TnI）、血清B型尿钠肽（BNP）及同型半胱氨酸（Hcy）水平，统计两组治疗间不良反应情况。结果 观察组总有效率（94.12%）显著高于对照组（80.39%），差异有统计学意义（P<0.05）；治疗后，两组患者LVESD、LVEDD均较治疗前降低，且观察组显著低于对照组，两组患者LVEF均较治疗前升高，且观察组显著高于对照组，差异均有统计学意义（P<0.05）；治疗后，两组患者LDH、AST、CK及CK-MB均较治疗前降低，且观察组治疗后显著低于对照组，差异均有统计学意义（P<0.05）；治疗后，两组患者TnI、BNP及Hcy均较治疗前降低，且观察组治疗后水平显著低于对照组，差异均有统计学意义（P<0.05）；在治疗期间，两组患者均未发生明显不良反应。结论 冠心宁联合单硝酸异山梨酯治疗CHF患者，可有效改善患者临床疗效，提高患者心功能，改善其心肌酶谱指标，安全性良好，值得应用。

Clinical efficacy of Guanxinning combined with isosorbide mononitrate in the treatment of patients with chronic heart failure and its influence on cardiac function

Objective To observe the clinical efficacy of Guanxinning combined with isosorbide mononitrate in treating patients with chronic heart failure (CHF) and its influence on cardiac function. Methods 102 patients with CHF who were treated in Fuyang Cancer Hospital, Anhui Province from January 2019 to December 2021 were divided into control group (n=51, isosorbide mononitrate treatment) and observation group (n=51, isosorbide mononitrate + Guanxinning treatment) according to the random number table method. The clinical efficacy as well as echocardiographic parameters left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], serum myocardial enzymes lactate dehydrogenase (LDH), aspartate aminotransferase (AST), creatine phosphokinase (CK), creatine phosphokinase isoenzyme (CK-MB)] and serum troponin I (TnI), brain natriuretic peptide (BNP) and homocysteine (Hcy) before and after treatment were compared between the two groups, and the adverse reactions in the two groups were counted during treatment. Results The total effective rate in observation group (94.12%) was significantly higher than that in control group (80.39%) (P<0.05). After treatment, LVESD and LVEDD in the two groups were reduced compared with those before treatment, and the two indicators in observation group were significantly lower than those in control group, and the LVEF was enhanced compared with that before treatment in the two groups, and the LVEF in observation group was significantly higher compared to control group (P<0.05). After treatment, the levels of LDH, AST, CK and CK-MB in both groups were lower than those before treatment, and the levels in observation group were significantly lower than those in control group (P<0.05). The levels of TnI, BNP and Hcy in the two groups after treatment were lower than those before treatment, and the above levels in observation group were significantly lower than those in control group (P<0.05). During treatment, there were no obvious adverse reactions in the two groups. Conclusion Guanxinning combined with isosorbide mononitrate can effectively improve the clinical efficacy, enhance the cardiac function and improve the myocardial enzymes in the treatment of patients with CHF, and it has good safety and is worthy of application.